Ensysce Biosciences, Inc. (ENSC)
NASDAQ: ENSC · Real-Time Price · USD
0.4705
-0.0405 (-7.93%)
At close: Oct 23, 2026, 4:00 PM EDT
0.4744
+0.0039 (0.83%)
After-hours: Oct 23, 2026, 7:56 PM EDT
Ensysce Biosciences Employees
As of December 31, 2025, Ensysce Biosciences had 10 total employees, including 8 full-time and 2 part-time employees. The number of employees increased by 2 or 25.00% compared to the previous year. That makes Ensysce Biosciences the 40,329th largest employer in the world and 6,048th in the United States.
Employees
10
Change (1Y)
2
Growth (1Y)
25.00%
Revenue / Employee
$450,075
Profits / Employee
-$1,262,390
Market Cap
9.15M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 10 | 2 | 25.00% | 8 | 2 |
| Dec 31, 2024 | 8 | 1 | 14.29% | 7 | 1 |
| Dec 31, 2023 | 7 | 0 | - | 7 | 0 |
| Dec 31, 2022 | 7 | 1 | 16.67% | 7 | 0 |
| Dec 31, 2021 | 6 | 3 | 100.00% | 6 | 0 |
| Sep 30, 2021 | 4 | 1 | 33.33% | 4 | 0 |
| Jun 30, 2021 | 4 | - | - | 4 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Lisata Therapeutics | 21 |
| Theriva Biologics | 16 |
| Lantern Pharma | 16 |
| CalciMedica | 15 |
| BioVie | 13 |
| MetaVia | 8 |
| Immuron | 8 |
| Phio Pharmaceuticals | 6 |
ENSC News
- 1 day ago - Ensysce Biosciences registers to sell 433.91M shares of common stock for holders - TheFly
- 1 day ago - Ensysce Biosciences Registration statement: Registration filing - Filings
- 3 days ago - Ensysce Biosciences participates in Family Office Summit, Dubai - TheFly
- 3 days ago - Ensysce Biosciences Expands Global Investor and Strategic Outreach at Family Office Summit, Dubai - Accesswire
- 4 days ago - Ensysce Biosciences initiated with an Overweight at Cantor Fitzgerald - TheFly
- 4 days ago - Ensysce Biosciences initiated with an Overweight at Cantor Fitzgerald - TheFly
- 4 weeks ago - Ensysce Biosciences submits Phase 2 protocol for CY200 to UK MHRA - TheFly
- 4 weeks ago - Ensysce Biosciences Phase 2 Protocol for CY200 - A Neuroplastigen for the Treatment of CRPS - Submitted to the UK MHRA - Accesswire